- Molena, D., Hyung, W. J., Wainberg, Z. A., Liberman, M., Folprecht, G., Diaz, I. A., Yoshikawa, T., Al-Batran, S.-E., Van Cutsem, E., Muro, K., Grimminger, P. P., Omori, T., Sotelo Lezama, M., Sipocz, I., Chalabi, M., Cheng, L.-Y., Heilbron, E., Robbins, S., Janjigian, Y. Y., & Tabernero, J. (2026). Surgical journey for participants (Pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (Flot) in resectable gastric/gastroesophageal junction (G/gej) adenocarcinoma. Journal of Clinical Oncology, 44(2_suppl), 353-353. https://doi.org/10.1200/JCO.2026.44.2_suppl.353 (Meeting abstract)
Surgical journey for participants (Pts) in the MATTERHORN trial: A global, randomized, phase 3 study of durvalumab (D) plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (Flot) in resectable gastric/gastroesophageal junction (G/gej) adenocarcinoma
on 1 de juny de 2026
with No hi ha comentaris
Deixa un comentari